Xuqing Zhang

List of Publications by Year
in descending order

22 papers	439 citations	687363 13 h-index	713466 21 g-index
23 all docs	23 docs citations	23 times ranked	497 citing authors

#	Article	IF	Citations
1	Design, Synthesis, and in Vivo SAR of a Novel Series of Pyrazolines as Potent Selective Androgen Receptor Modulators. Journal of Medicinal Chemistry, 2007, 50, 3857-3869.	6.4	80
2	Deciphering the selective androgen receptor modulators paradigm. Expert Opinion on Drug Discovery, 2013, 8, 191-218.	5.0	53
3	Electron Density Guided Fragment-Based Lead Discovery of Ketohexokinase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 7979-7991.	6.4	33
4	A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats. Endocrine, 2007, 32, 41-51.	2.2	30
5	Synthesis and SAR of novel hydantoin derivatives as selective androgen receptor modulators. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5763-5766.	2.2	29
6	Discovery of indole-containing tetracycles as a new scaffold for androgen receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3233-3237.	2.2	26
7	Serendipitous discovery of novel imidazolopyrazole scaffold as selective androgen receptor modulators. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 439-443.	2.2	24
8	Optimization of a pyrazole hit from FBDD into a novel series of indazoles as ketohexokinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4762-4767.	2.2	22
9	Recent advances in the development of selective androgen receptor modulators. Expert Opinion on Therapeutic Patents, 2009, 19, 1239-1258.	5.0	20
10	Design, synthesis and SAR of a novel series of heterocyclic phenylpropanoic acids as GPR120 agonists. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3272-3278.	2.2	20
11	Targeting Enteropeptidase with Reversible Covalent Inhibitors To Achieve Metabolic Benefits. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 510-521.	2.5	19
12	Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes. ACS Medicinal Chemistry Letters, 2017, 8, 947-952.	2.8	17
13	Evaluation of anti-diabetic effect and gall bladder function with 2-thio-5-thiomethyl substituted imidazoles as TGR5 receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1760-1764.	2.2	16
14	GPR120 agonists for the treatment of diabetes: a patent review (2014 present). Expert Opinion on Therapeutic Patents, 2020, 30, 729-742.	5.0	16
15	Î²-Alkylthio indolyl carbinols: Potent nonsteroidal antiandrogens with oral efficacy in a prostate cancer model. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2545-2548.	2.2	11
16	Discovery of Orally Efficacious Tetrahydrobenzimidazoles as TGR5 Agonists for Type 2 Diabetes. ACS Medicinal Chemistry Letters, 2017, 8, 560-565.	2.8	8
17	Pharmacological characterization of an imidazolopyrazole as novel selective androgen receptor modulator. Journal of Steroid Biochemistry and Molecular Biology, 2013, 134, 51-58.	2.5	5
18	Discovery of a Novel Series of Pyridone-Based EP3 Antagonists for the Treatment of Type 2 Diabetes. ACS Medicinal Chemistry Letters, 2021, 12, 451-458.	2.8	3

#	Article	IF	Citations
19	Optimization of physicochemical properties of pyridone-based EP3 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2021, 47, 128172.	2.2	3
20	Discovery of a novel series of guanidinebenzoates as gut-restricted enteropeptidase and trypsin dual inhibitors for the treatment of metabolic syndrome. Bioorganic and Medicinal Chemistry Letters, 2021, 40, 127939.	2.2	2
21	Therapeutic Potential of EP3 Receptor Antagonists for Treatment of Noninsulin Dependent Diabetes Mellitus across Multiple Preclinical Models. Diabetes, 2018, 67, 250-LB.	0.6	2
22	Discovery and Optimization of 7-Alkylidenyltetrahydroindazole-Based Acylsulfonamide EP3 Antagonists. ACS Medicinal Chemistry Letters, 2022, 13, 111-117.	2.8	0